Get the Stockscreener App
9.10
21.50%
1.61
After Hours:
8.61
-0.49
-5.38%
Artiva Biotherapeutics Inc stock is traded at $9.10, with a volume of 876.67K.
It is up +21.50% in the last 24 hours and up +47.25% over the past month.
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
See More
Previous Close:
$7.49
Open:
$7.88
24h Volume:
876.67K
Relative Volume:
4.49
Market Cap:
$224.92M
Revenue:
$251.00K
Net Income/Loss:
$-83.87M
P/E Ratio:
-2.6524
EPS:
-3.4309
Net Cash Flow:
$-79.34M
1W Performance:
+47.01%
1M Performance:
+47.25%
6M Performance:
+202.33%
1Y Performance:
+287.23%
1-Day Range:
$7.71
$9.16
1-Week Range:
$6.13
$9.16
52-Week Range:
$1.47
$9.16
Artiva Biotherapeutics Inc Stock (ARTV) Company Profile
Name
Artiva Biotherapeutics Inc
Sector
Industry
Phone
(858) 267-4467
Address
5505 MOREHOUSE DRIVE, SAN DIEGO
Compare ARTV vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARTV
Artiva Biotherapeutics Inc
|
9.10 | 185.13M | 251.00K | -83.87M | -79.34M | -3.4309 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Artiva Biotherapeutics Inc Stock (ARTV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-11-25 | Resumed | H.C. Wainwright | Buy |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-13-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-24 | Initiated | Jefferies | Buy |
| Aug-13-24 | Initiated | Needham | Buy |
| Aug-13-24 | Initiated | TD Cowen | Buy |
| Aug-13-24 | Initiated | Wedbush | Outperform |
View All
Artiva Biotherapeutics Inc Stock (ARTV) Latest News
Artiva Biotherapeutics Spotlights RA as Lead NK Cell Program, Eyes H1 Efficacy Data Catalyst at Needham - Yahoo Finance
Whale Trades: Is Blend Labs Inc backed by strong institutional buying2026 Setups & Long-Term Capital Growth Strategies - baoquankhu1.vn
Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference - Sahm
ARTV Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Artiva Biotherapeutics (NASDAQ:ARTV) Rating Increased to Hold at Wall Street Zen - Defense World
Artiva Biotherapeutics Inc. (ARTV) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
ARTV Technical Analysis & Stock Price Forecast - Intellectia AI
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
BZ2704 Forecast — Price Prediction for 2026. Should I Buy BZ2704? - Intellectia AI
Artiva Biotherapeutics (ARTV) Expected to Announce Earnings on Monday - MarketBeat
ARTV SEC FilingsARTIVA BIOTHERAPEUTICS INC 10-K, 10-Q, 8-K Forms - Stock Titan
If You Invested $1,000 in ARTIVA BIOTHERAPEUTICS INC (ARTV) - Stock Titan
FFAIW Should I Buy - Intellectia AI
POWWP Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
LEGT Should I Buy - Intellectia AI
Market Rankings: Can PROP deliver consistent EPS growth2026 Analyst Calls & Risk Controlled Swing Alerts - baoquankhu1.vn
Should I add Artiva Biotherapeutics Inc stock to my portfolio2026 Big Picture & Community Verified Trade Signals - baoquankhu1.vn
02652 Should I Buy - Intellectia AI
TOLL Should I Buy - Intellectia AI
GRABW Should I Buy - Intellectia AI
Wedbush Maintains Artiva Biotherapeutics (ARTV) Outperform Recommendation - MSN
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Sees Significant Decrease in Short Interest - MarketBeat
Artiva Biotherapeutics, Inc. (ARTV) Receives a Buy from Jefferies - The Globe and Mail
Research Analysts Issue Forecasts for ARTV Q1 Earnings - MarketBeat
Analysts Offer Insights on Healthcare Companies: Artiva Biotherapeutics, Inc. (ARTV) and Edgewise Therapeutics (EWTX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Artiva Biotherapeutics, Inc. (ARTV) and Clinigence Holdings (NUTX) - The Globe and Mail
Artiva Biotherapeutics (NASDAQ:ARTV) Given Buy Rating at Needham & Company LLC - Defense World
Artiva Biotherapeutics, Inc. 2025 Annual Report: Business Overview, Risk Factors, and Strategic Outlook - Minichart
Artiva Biotherapeutics' (ARTV) Buy Rating Reiterated at Needham & Company LLC - MarketBeat
Artiva: Sufficient Cash Runway to 2027 Supports Buy Rating Ahead of Key 2026 RA Efficacy Readouts - TipRanks
ARTV: AlloNK shows promise in refractory RA as clinical and financial milestones approach in 2026 - TradingView
Artiva Biotherapeutics 10-K: Revenue $0.0M, Net Loss $(83.9)M — Cash $108.0M - TradingView
ARTV: 2025 net loss widened to $83.9M as R&D spending increased; cash runway extends into Q2 2027 - TradingView
Artiva Biotherapeutics posts 2025 results, prepares for RA clinical data in early 2026 - Traders Union
Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights - marketscreener.com
Growth Value: Is Stantec Inc on track to beat earningsWeekly Volume Report & Expert Curated Trade Ideas - baoquankhu1.vn
What insider trading reveals about Artiva Biotherapeutics Inc. stock2026 Price Swings & Advanced Swing Trade Entry Plans - Naître et grandir
Dow Update: Does Artiva Biotherapeutics Inc have consistent dividend growthWeekly Gains Summary & Technical Buy Zone Confirmation - baoquankhu1.vn
Artiva Biotherapeutics Pivots to Rheumatoid Arthritis at TD Cowen, Teases 2026 RA Data Update - MarketBeat
Latigo Biotherapeutics Appoints Neha Krishnamohan as Chief Financial Officer and Chief Business Officer - BioSpace
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Artiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care Conference - GlobeNewswire
Artiva Biotherapeutics appoints Thad Huston as chief financial officer - Investing.com Australia
Artiva Biotherapeutics appoints Thad Huston as chief financial officer By Investing.com - Investing.com South Africa
Artiva Biotherapeutics Appoints Thad Huston as Chief Financial Officer - TipRanks
Artiva Biotherapeutics, Inc. Appoints Thad Huston as Principal Financial Officer and Principal Accounting Officer, Effective from February 18, 2026 - marketscreener.com
Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant - The Globe and Mail
Artiva Biotherapeutics Announces Appointment Of Thad Huston As CFO - TradingView
Artiva Biotherapeutics Announces Appointment of Thad Huston - GlobeNewswire
Is Artiva Biotherapeutics Inc. on track to beat earningsJuly 2025 Retail & Daily Profit Maximizing Tips - mfd.ru
Can Artiva Biotherapeutics Inc. keep up with sector leaders2025 Institutional Moves & AI Driven Stock Movement Reports - mfd.ru
Artiva Biotherapeutics Inc Stock (ARTV) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):